Scalable, single-use technologies for purification of lentiviral vectors


Cell & Gene Therapy Insights 2021; 7(3), 409

Published: 29 April 2021
Todd Sanderson

Watch the video or read the poster to learn:

  • Why lentiviral vector production poses unique challenges
  • How technologies used in mAb production are being leveraged to provide scalable vector manufacturing
  • Outcomes from a series of feasibility studies to evaluate single-use consumables for purification of lentiviral vectors

About the speaker

Todd Sanderson has been with Pall since 2006. He has over 20 years of research experience with expertise in mammalian cell culture, process development and analytical method development. He currently leads the US team of Upstream and Analytics within the R&D Bioprocessing Group. He holds a B.S. in Biochemistry and B.S. in Psychology from Michigan State University. When not at work, Todd enjoys gardening and spending time with his young children